FR2116256A1 - Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects - Google Patents

Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects

Info

Publication number
FR2116256A1
FR2116256A1 FR7043274A FR7043274A FR2116256A1 FR 2116256 A1 FR2116256 A1 FR 2116256A1 FR 7043274 A FR7043274 A FR 7043274A FR 7043274 A FR7043274 A FR 7043274A FR 2116256 A1 FR2116256 A1 FR 2116256A1
Authority
FR
France
Prior art keywords
dopa
coated
enteric
gastrointestinal side
compsns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7043274A
Other languages
French (fr)
Other versions
FR2116256B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOBIO LAB
Original Assignee
SOBIO LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOBIO LAB filed Critical SOBIO LAB
Priority to FR7043274A priority Critical patent/FR2116256A1/en
Publication of FR2116256A1 publication Critical patent/FR2116256A1/en
Application granted granted Critical
Publication of FR2116256B1 publication Critical patent/FR2116256B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Enteric-coated compsns of L-DOPA which avoid the gastrointestinal side-effects caused by the normal dose of 500 mg of L-DOPA in uncoated compsns. Tablets or capsules may be coated e.g. with a mixt of methacrylic acid and methyl methacrylate dissolved in isopropanol/acetone. When stirred in artificial gastric juice at 37 degrees C the compsns must nto breakdown under 2 hr but when stirred in artificial intestinal juice they must disintegrate in 45 min.
FR7043274A 1970-12-02 1970-12-02 Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects Granted FR2116256A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7043274A FR2116256A1 (en) 1970-12-02 1970-12-02 Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7043274A FR2116256A1 (en) 1970-12-02 1970-12-02 Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects

Publications (2)

Publication Number Publication Date
FR2116256A1 true FR2116256A1 (en) 1972-07-13
FR2116256B1 FR2116256B1 (en) 1974-03-22

Family

ID=9065059

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7043274A Granted FR2116256A1 (en) 1970-12-02 1970-12-02 Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects

Country Status (1)

Country Link
FR (1) FR2116256A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080341A2 (en) * 1981-11-20 1983-06-01 A/S Alfred Benzon Pharmaceutical multiple-units formulation
EP0156077A1 (en) * 1983-12-21 1985-10-02 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
EP0260236A1 (en) * 1986-08-26 1988-03-16 ASTA Pharma Aktiengesellschaft Composition comprising L-dopa

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5157813A (en) 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
(LA *REVUE"UNLISTED DRUGS"VOLUME 14 1962 NO 1 PAGE 60 *
*LA *REVUE"CHEM.ABSTRACTS"VOLUME 57, 1962 COL.13.152H MENTIONNANT"CIRCULATION"VOLUME 25. 1962 PAGES 281-291.,L'ARTICLE DE GILLE-SPIE ET AL:"CLINICAL AND CHEMICAL STUDIES WITH-METHYL DOPA") *
AL:"CLINICAL AND CHEMICAL STUDIES WITH-METHYL DOPA") *
COL.13.152H MENTIONNANT"CIRCULATION"VOLUME 25. 1962 PAGES 281-291.,L'ARTICLE DE GILLE-SPIE ET *
LA REVUE"CHEM.ABSTRACTS"VOLUME 57, 1962 *
LA REVUE"UNLISTED DRUGS"VOLUME 14 1962 NO 1 PAGE 60 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080341A2 (en) * 1981-11-20 1983-06-01 A/S Alfred Benzon Pharmaceutical multiple-units formulation
EP0080341A3 (en) * 1981-11-20 1983-09-14 A/S Alfred Benzon Pharmaceutical multiple-units formulation
EP0156077A1 (en) * 1983-12-21 1985-10-02 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
US4716040A (en) * 1983-12-21 1987-12-29 Elan Corporation P.L.C. Controlled absorption methyldopa pharmaceutical formulation
EP0260236A1 (en) * 1986-08-26 1988-03-16 ASTA Pharma Aktiengesellschaft Composition comprising L-dopa

Also Published As

Publication number Publication date
FR2116256B1 (en) 1974-03-22

Similar Documents

Publication Publication Date Title
DK128283A (en) PHARMACEUTICAL PREPARATIONS TO BE ADMINISTRATED ORAL
DE3277520D1 (en) Pharmaceutical multiple-units formulation
PT825858E (en) DEPENDENT TIME-RELEASING CAPSULES CONTAINING POLYINSATURATED ACIDS OMEGA-3 FOR THE TREATMENT OF INFLAMMATORY DISEASE OF THE INTESTINE
CA2132012A1 (en) Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
CA2104686A1 (en) Delayed Release Oral Dosage Forms for Treatment of Intestinal Disorders
DE69009755D1 (en) ORAL MEDICINE FOR PERMANENT ADMINISTRATION.
NZ218734A (en) Tablets containing coated microspheres which contain ibuprofen (2-(4-isobutyl phenyl)propanoic acid)
FR2116256A1 (en) Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
GB1402691A (en) Composition of 4-biphenyl acetic acid
FR2096902A1 (en) Aqs alcoholic extract of chrysanthellum americanum vatke - - active in intestinal disorders
FR2100561A2 (en) Medicine capsules - dissolving in intestine with wall consisting of two polymers eg hydroxypropylcellulose and cellulose acetophthalat
FR2135021A2 (en) Medicine capsules - dissolving in intestine with wall consisting of two polymers eg hydroxypropylcellulose and cellulose acetophthalat
Moniuszko-Jakoniuk et al. The activation of the kinin-forming system and the effects of thiopental.
ES2008753A6 (en) Release-controlled tablet type medicinal preparation based on buflomedil hydrochloride and manufacture
FR2162245A1 (en) Micronized l-dopa - with increased bioavailability
HUP9903839A2 (en) Pharmaceutical compositions containing (s)-oxybutynin and (s)-desethyloxybutynin for the treatment of urinary incontinence

Legal Events

Date Code Title Description
ST Notification of lapse